Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective
Identifieur interne : 008958 ( Main/Exploration ); précédent : 008957; suivant : 008959Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective
Auteurs : Tiziana Catzeddu [Italie] ; Gianfilippo Bertelli [Royaume-Uni] ; Lucia Del Mastro [Italie] ; Marco Venturini [Italie]Source :
- Journal of Surgical Oncology [ 0022-4790 ] ; 2004-03-01.
Abstract
Recent data indicates that the sentinel lymph node biopsy (SLNB) is a possible alternative to axillary lymph node dissection (ALND) in early breast cancer patients, with minimal risk of complications. From the medical oncologist's point of view, the impact of SLNB on the management of patients should consider if SLNB is useful to choose adjuvant treatment, if it is adequate to provide local control, and what is the significance of lymph node micrometastases on treatment and staging. Lymph node involvement has always been recognised as the most important prognostic factor in early‐stage breast cancer, even if many other parameters have been evaluated in recent years. However, the lack of knowledge of nodal status in patients with false‐negative SLNB seems to result in an undertreatment in a very low percentage of patients. Adjuvant chemotherapy and hormonal therapy with tamoxifen are associated with an absolute reduction of the risk of recurrence and death both in node‐positive and in node‐negative patients, then if patients are treated with modern adjuvant systemic therapy, any effect associated with false negative SLN should be minimised. The impact of axillary treatment on survival is still controversial, but in recent times axillary lymph node positivity is considered as an indicator for high risk of systemic diffusion of the disease rather than a possible origin of systemic metastases. The significance of occult sentinel lymph node metastases detected by immunohistochemistry (IHC) or molecular biology on prognosis is still uncertain. The new version of the staging system of breast cancer has recognised the need for a standard diagnostic approach and of a nomenclature system which also takes SLNB into account. J. Surg. Oncol. 2004;85:129–132. © 2004 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jso.20025
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 007117
- to stream Istex, to step Curation: 007117
- to stream Istex, to step Checkpoint: 001E40
- to stream Main, to step Merge: 008C20
- to stream Main, to step Curation: 008958
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective</title><author><name sortKey="Catzeddu, Tiziana" sort="Catzeddu, Tiziana" uniqKey="Catzeddu T" first="Tiziana" last="Catzeddu">Tiziana Catzeddu</name></author><author><name sortKey="Bertelli, Gianfilippo" sort="Bertelli, Gianfilippo" uniqKey="Bertelli G" first="Gianfilippo" last="Bertelli">Gianfilippo Bertelli</name></author><author><name sortKey="Del Mastro, Lucia" sort="Del Mastro, Lucia" uniqKey="Del Mastro L" first="Lucia" last="Del Mastro">Lucia Del Mastro</name></author><author><name sortKey="Venturini, Marco" sort="Venturini, Marco" uniqKey="Venturini M" first="Marco" last="Venturini">Marco Venturini</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F146481A4DE572283B4E2D8D3B5C64552C267250</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/jso.20025</idno><idno type="url">https://api.istex.fr/document/F146481A4DE572283B4E2D8D3B5C64552C267250/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">007117</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">007117</idno><idno type="wicri:Area/Istex/Curation">007117</idno><idno type="wicri:Area/Istex/Checkpoint">001E40</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E40</idno><idno type="wicri:doubleKey">0022-4790:2004:Catzeddu T:sentinel:lymph:node</idno><idno type="wicri:Area/Main/Merge">008C20</idno><idno type="wicri:Area/Main/Curation">008958</idno><idno type="wicri:Area/Main/Exploration">008958</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective</title><author><name sortKey="Catzeddu, Tiziana" sort="Catzeddu, Tiziana" uniqKey="Catzeddu T" first="Tiziana" last="Catzeddu">Tiziana Catzeddu</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Oncology, National Cancer Reasearch Institute, Genoa</wicri:regionArea><wicri:noRegion>Genoa</wicri:noRegion></affiliation></author><author><name sortKey="Bertelli, Gianfilippo" sort="Bertelli, Gianfilippo" uniqKey="Bertelli G" first="Gianfilippo" last="Bertelli">Gianfilippo Bertelli</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>SW Wales Cancer Institute, Singleton Hospital, Swansea</wicri:regionArea><wicri:noRegion>Swansea</wicri:noRegion></affiliation></author><author><name sortKey="Del Mastro, Lucia" sort="Del Mastro, Lucia" uniqKey="Del Mastro L" first="Lucia" last="Del Mastro">Lucia Del Mastro</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Oncology, National Cancer Reasearch Institute, Genoa</wicri:regionArea><wicri:noRegion>Genoa</wicri:noRegion></affiliation></author><author><name sortKey="Venturini, Marco" sort="Venturini, Marco" uniqKey="Venturini M" first="Marco" last="Venturini">Marco Venturini</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Oncology, National Cancer Reasearch Institute, Genoa</wicri:regionArea><wicri:noRegion>Genoa</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Surgical Oncology</title><title level="j" type="alt">JOURNAL OF SURGICAL ONCOLOGY</title><idno type="ISSN">0022-4790</idno><idno type="eISSN">1096-9098</idno><imprint><biblScope unit="vol">85</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="132">132</biblScope><biblScope unit="page-count">4</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03-01">2004-03-01</date></imprint><idno type="ISSN">0022-4790</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-4790</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent data indicates that the sentinel lymph node biopsy (SLNB) is a possible alternative to axillary lymph node dissection (ALND) in early breast cancer patients, with minimal risk of complications. From the medical oncologist's point of view, the impact of SLNB on the management of patients should consider if SLNB is useful to choose adjuvant treatment, if it is adequate to provide local control, and what is the significance of lymph node micrometastases on treatment and staging. Lymph node involvement has always been recognised as the most important prognostic factor in early‐stage breast cancer, even if many other parameters have been evaluated in recent years. However, the lack of knowledge of nodal status in patients with false‐negative SLNB seems to result in an undertreatment in a very low percentage of patients. Adjuvant chemotherapy and hormonal therapy with tamoxifen are associated with an absolute reduction of the risk of recurrence and death both in node‐positive and in node‐negative patients, then if patients are treated with modern adjuvant systemic therapy, any effect associated with false negative SLN should be minimised. The impact of axillary treatment on survival is still controversial, but in recent times axillary lymph node positivity is considered as an indicator for high risk of systemic diffusion of the disease rather than a possible origin of systemic metastases. The significance of occult sentinel lymph node metastases detected by immunohistochemistry (IHC) or molecular biology on prognosis is still uncertain. The new version of the staging system of breast cancer has recognised the need for a standard diagnostic approach and of a nomenclature system which also takes SLNB into account. J. Surg. Oncol. 2004;85:129–132. © 2004 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Italie</li><li>Royaume-Uni</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Catzeddu, Tiziana" sort="Catzeddu, Tiziana" uniqKey="Catzeddu T" first="Tiziana" last="Catzeddu">Tiziana Catzeddu</name></noRegion><name sortKey="Del Mastro, Lucia" sort="Del Mastro, Lucia" uniqKey="Del Mastro L" first="Lucia" last="Del Mastro">Lucia Del Mastro</name><name sortKey="Venturini, Marco" sort="Venturini, Marco" uniqKey="Venturini M" first="Marco" last="Venturini">Marco Venturini</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Bertelli, Gianfilippo" sort="Bertelli, Gianfilippo" uniqKey="Bertelli G" first="Gianfilippo" last="Bertelli">Gianfilippo Bertelli</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008958 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008958 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F146481A4DE572283B4E2D8D3B5C64552C267250
|texte= Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective
}}
| This area was generated with Dilib version V0.6.31. |  |